Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board lifted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,000 shares of the specialty pharmaceutical company's stock after purchasing an additional 8,000 shares during the period. Canada Pension Plan Investment Board owned 0.31% of Jazz Pharmaceuticals worth $23,275,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of JAZZ. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $25,000. Quadrant Capital Group LLC increased its stake in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares in the last quarter. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at $28,000. Allianz SE purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth $29,000. Finally, Jones Financial Companies Lllp raised its holdings in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the period. 89.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Royal Bank of Canada lowered their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Barclays reaffirmed an "overweight" rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, Truist Financial increased their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $187.71.

Insider Activity

In related news, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,736 shares of company stock valued at $4,023,305. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Trading Up 1.0 %

Jazz Pharmaceuticals stock traded up $1.10 during trading on Friday, reaching $110.08. 192,890 shares of the company were exchanged, compared to its average volume of 793,006. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a market capitalization of $6.69 billion, a P/E ratio of 15.49, a PEG ratio of 1.04 and a beta of 0.42. The stock's 50 day simple moving average is $125.13 and its two-hundred day simple moving average is $122.18. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.